Inaktiver Wert

Andere Sprachen Actavis Inc Nyse

Aktien

US9426831031

Schlusskurs Nyse Andere Börsenplätze
- ^USD	-

05.03.	Allergan Aesthetics gibt die FDA-Zulassung von JUVEDERM VOLUMA XC für die Injektion in die Schläfenregion zur Verbesserung mittelschwerer bis schwerer Schläfenhohlräume bei Erwachsenen über 21 Jahren bekannt	CI
2023	Allergan Aesthetics gibt positive Topline-Ergebnisse der zweiten Phase-3-Studie zu Onabotulinumtoxina für die Behandlung von Platysma-Prominenz bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	01.04.
Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21	05.03.
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence	18.09.23
Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic)	30.08.23
Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM®	15.05.23
Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc	18.01.23
Allergan Aesthetics Announces the Launch of the Long-Awaited SkinMedica Even & Correct Collection	17.01.23
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio At the 2022 American Society for Dermatologic Surgery Meeting	07.10.22
Allergan Aesthetics Announces the Launch of SkinMedica Firm & Tone Lotion for Body	31.08.22
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition	03.08.22
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics	13.06.22
Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	20.04.22
Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	06.04.22
PatientFi Expands Partnership with Allergan Aesthetics	06.04.22
AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	22.03.22
Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million.	16.12.21
Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	10.12.21
Allergan Aesthetics to Present Data from its Aesthetic Portfolio at the 2021 American Society for Dermatologic Surgery Virtual Meeting	19.11.21
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia	27.10.21
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia	26.10.21

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Actavis Inc Nyse

Aktien

US9426831031

Andere Sprachen

Filter